Physician profile
Robert C Wesley
NPI 1184630469
$3,720.89
in general payments reported to CMS, 2019-2025
14 companies · $86.53 in 2025
The $86.53 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $168 · 2021: $493 · 2022: $1,038 · 2023: $445 · 2024: $812 · 2025: $86.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $790.07 | 2022-2024 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan, Micra |
| Cvrx, INC. | $620.44 | 2019-2024 | Barostim Neo System |
| Abbott Laboratories | $620.31 | 2019-2024 | Gallant |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $520.40 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $401.86 | 2024-2025 | Assure Wcd |
| Vifor Pharma, INC. | $124.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $116.95 | 2021 | |
| Biotronik INC. | $100.40 | 2021 | |
| Boston Scientific Corporation | $94.70 | 2023 | Watchman Flx |
| Nevro Corp. | $89.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $82.33 | 2020 | |
| Baxter Healthcare | $61.37 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Medtronic Vascular, INC. | $54.80 | 2019 | |
| Esperion Therapeutics, INC. | $42.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wesley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.